|
|
News Breaks | | | | December 20, 2012 | | 07:31 EDT |  | FOLD | Amicus Theraputics weakness a buying opportunity, says JPMorgan
JPMorgan views the pullback in shares of Amicus Theraputics on the company's Phase 3 trial miss as a buying opportunity. The firm says migalastat is active in Fabry and safe, and reiterates an Overweight rating on the stock, despite lowering its price target for shares to $5 from $9. | |
|
News For FOLD From The Last 14 Days Check below for free stories on FOLD the last two weeks. |
|
|
| May 9, 2013 | | 16:18 EDT |  | FOLD | Amicus Theraputics reports Q1 EPS (35c), consensus (33c)
 Subscribe for More Information | |
|
|
|
|
|
|
